登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C18H20N2O6
化学文摘社编号:
分子量:
360.36
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
SMILES string
CCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC
InChI key
PVHUJELLJLJGLN-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
nitrendipine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Nitrendipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
wgk
WGK 1
T M Santiago et al.
DICP : the annals of pharmacotherapy, 24(2), 167-175 (1990-02-01)
Nitrendipine, an investigational dihydropyridine calcium-channel antagonist for the treatment of hypertension, is reviewed. Clinical trials report efficacy equal to that of hydralazine, diuretics, beta-blockers, and other calcium-channel blockers such as nifedipine, verapamil, and isradipine. Nitrendipine has a favorable pharmacokinetic profile
G R Hasegawa
Clinical pharmacy, 7(2), 97-108 (1988-02-01)
The chemistry, pharmacology, pharmacokinetics, clinical uses, and adverse effects of nicardipine, nitrendipine, and bepridil are reviewed. Nicardipine, nitrendipine, and bepridil are calcium antagonists under investigation for the treatment of cardiovascular disorders. Nicardipine and nitrendipine share a common dihydropyridine nucleus with
M Mancini et al.
Journal of cardiovascular pharmacology, 18 Suppl 1, S30-S33 (1991-01-01)
There is evidence that hypertensive patients frequently have other metabolic disorders, such as hyperlipidemia and diabetes mellitus. It is also known that the reduction in high blood pressure alone, disregarding the other cardiovascular risk factors, is unable to reduce mortality
M Eichelbaum et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S6-10 (1988-01-01)
Nitrendipine [3-ethyl-5-methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate] is a calcium antagonist with a dihydropyridine structure that has a great structural resemblance to nifedipine. Instead of a methyl group in position 3, it has an ethyl group and the NO2 group is in the meta
S Kazda et al.
Journal of cardiovascular pharmacology, 12 Suppl 4, S1-S5 (1988-01-01)
The mechanism of the antihypertensive effect of nitrendipine is believed to be vasodilation, resulting in a reduction of the total peripheral resistance. However, in contrast to other arteriolar vasodilators, nitrendipine exerts natriuretic and diuretic effects that are more pronounced in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持